Business
ProtoKinetix’ AAGP™ to Be Presented at the Congress of the International Pancreas and Islet Transplant Association
ProtoKinetix’ AAGP™ to Be Presented at the Congress of the International Pancreas and Islet Transplant Association.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, \n Incorporated (OTC: PKTX) (the \"Company\" or \"ProtoKinetix\") (www.protokinetix.com) \n is pleased to announce that AAGP™ will be presented at the 2015 Joint \n Congress of the IPITA-IXA-CTS on Monday, November 16, 2015. The \n Joint Congress of the International Pancreas and Islet Transplant \n Association (IPITA), the International Xenotransplantation Association \n (IXA) and the Cell Transplant Society (CTS) to be held in Melbourne, \n Australia, 15–19 November 2015.\n \n \n Dr. Boris L. Gala-Lopez, Research Fellow of Department of Surgery in the \n Alberta Diabetes Institute at the University of Alberta will be giving a \n lecture titled “Anti-aging Glycopeptide Protects Human Islets Against \n Tacrolimus-related Injury and Facilitates Engraftment” to support his \n conclusion that, “Supplementation with AAGP™ during the culture \n period improves islet quality and potency. Upon transplantation, \n pre-treatment with AAGP™ may facilitate engraftment in mice, improve \n graft secretory function and may attenuate long-term tacrolimus induced \n graft dysfunction. These findings may constitute a clear opportunity to \n develop more efficient strategies against post-transplant diabetes \n mellitus.”\n \n \n For details see the web site: confman.melbourne2015.org/mobis/lecture/758\n \n \n About Dr. Boris L. Gala-Lopez\n \n \n Dr. Gala-Lopez is currently a PhD \n Research Fellow in the Clinical Islet Transplant Program at the \n University of Alberta. He has been responsible for multiple preclinical \n and clinical investigations in the field of islet transplantation to \n improve the novel treatment for Type 1 diabetes mellitus.\n \n \n Dr. Gala-Lopez has also done extensive work in the area of \n ischemia-reperfusion injury for cell and solid organ transplantation.\n \n \n About ProtoKinetix\n \n \n ProtoKinetix, Inc. is a molecular biotechnology company that has \n developed and patented a family of hyper stable, potent glycopeptides \n (AAGP™) that enhance therapeutic results and reduce the cost of stem \n cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, \n the Company is currently targeting the direct treatment of diseases that \n have a major inflammatory component.\n \n \n The Private Securities Litigation Reform Act of...